President & CEO. Co-Founder

Ask Thomas Smeenk, CEO, Hemostemix Inc. (TSXV: HEM | OTCQB: HMTXF), about investment opportunities, or if you're eligible for treatment in CANADA, The Bahamas or Florida. Backed by 498 treatments, including the clinical trial data of 318 subjects detailed in 11 peer-reviewed publications, ACP-01 has been shown to be safe, efficacious, and clinically relevant as a treatment for cardiovascular diseases of the heart, limb - PAD - and brain - vascular dementia. VesCell (ACP-01) is still under investigation and is not FDA or Health Canada approved. Individual results may vary.